FDA
-
-
-
-
-
-
-
Longeveron stem cell therapy data to be presented at 2026 AAIC
-
-
-
-
-
-
-
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
-
-
-
-
-
-
-
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
-
-
-
-
-
-
-
Longeveron Announces Closing of Private Placement of up to $30 Million
-
-
-
-
-
-
-
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
-
-
-
-
-
-
-
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
-
-
-
-
-
-
-
Longeveron selected for Alzheimer's poster at CTAD 2025 conference
-
326,855 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

